Editorial. SGLT-2 receptor inhibitors: An opportunity to revise our therapeutic strategy for type 2 diabetes?

Fabrice Bonnet; André J Scheen

doi:10.1016/S1262-3636(14)72688-6

Journal Articles Diabetes & Metabolism Year : 2014

Editorial. SGLT-2 receptor inhibitors: An opportunity to revise our therapeutic strategy for type 2 diabetes?

(1) , (2)

1
2

Fabrice Bonnet

Function : Author

Foie, métabolismes et cancer

André J Scheen

Function : Author

Service de Diabétologie, Nutrition et Maladies métaboliques et Unité de Pharmacologie clinique

Domains

Life Sciences [q-bio]

Laurent Jonchère : Connect in order to contact the contributor

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01134740

Submitted on : Tuesday, March 24, 2015-11:19:30 AM

Last modification on : Friday, March 10, 2023-4:18:24 PM

Dates and versions

hal-01134740 , version 1 (24-03-2015)

Identifiers

HAL Id : hal-01134740 , version 1
DOI : 10.1016/S1262-3636(14)72688-6
PUBMED : 25554065

Cite

Fabrice Bonnet, André J Scheen. Editorial. SGLT-2 receptor inhibitors: An opportunity to revise our therapeutic strategy for type 2 diabetes?. Diabetes & Metabolism, 2014, 40 (6 Suppl 1), pp.S1-3. ⟨10.1016/S1262-3636(14)72688-6⟩. ⟨hal-01134740⟩

Export

BibTeX TEI Dublin Core DC Terms EndNote Datacite

Collections

UNIV-RENNES1 NUMECAN UR1-UFR-SVE UNIV-RENNES UR1-BIO-SA

23 View

0 Download

Editorial. SGLT-2 receptor inhibitors: An opportunity to revise our therapeutic strategy for type 2 diabetes?

Domains

Dates and versions

Identifiers

Cite

Export

Collections

Altmetric

Share